Speedy Vaccine Production Among Goals Of FDA's Budget Proposal For Countermeasures
Executive Summary
FDA plans to expand its medical countermeasures program beyond pandemic influenza with the infusion of $70 million requested in the fiscal year 2012 budget sent to Capitol Hill by the Obama Administration Feb. 14.
You may also be interested in...
Biosimilars, Generic Programs Leave Little Room For Other New FDA Drug Initiatives In FY ‘13
Proposed and existing user fees would fund 44% of the $4.5 billion FDA FY 2013 spending plan. User fees are projected at $20 million for biosimilars and $229 million for generic drugs.
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA should spend $19 million of an increase in non-user fee funding in fiscal 2012 on the agency’s medical countermeasures effort, the Senate Appropriations Committee recommends in the report that accompanies the Agriculture/FDA appropriations bill approved by the panel Sept 8.
FDA's Medical Countermeasure Program Among Senate Funding Priorities
FDA should spend $19 million of an increase in non-user fee funding in fiscal 2012 on the agency’s medical countermeasures effort, the Senate Appropriations Committee recommends in the report that accompanies the Agriculture/FDA appropriations bill approved by the panel Sept 8.